Tumor Antigen Generation

Tumor Antigen Generation is the set of molecular mechanisms by which a cancer cell's altered genome, transcriptome, and protein processing machinery produce novel or aberrant peptide sequences capable of being displayed on MHC molecules and recognized as non-self, encompassing several distinct routes beyond the simple missense mutation most commonly associated with neoantigen formation. While cancer cell immunogenicity described tumor antigens as a category defined by their origin (mutation-derived, overexpression-derived, or viral), tumor antigen generation examines the specific molecular events producing each of these categories in mechanistic detail, revealing a considerably more varied set of processes than point mutation alone.

Point Mutation-Derived Neoantigens

The most extensively characterized route to neoantigen generation is a somatic missense mutation altering a single amino acid within an otherwise normal protein sequence, producing a peptide that differs from its wild-type counterpart at one position:

Whether this single-residue change is sufficient to generate a genuinely immunogenic peptide depends on whether the altered residue falls within a position critical for MHC binding affinity or for T cell receptor contact, meaning only a subset of missense mutations, even among those producing MHC-presentable peptides at all, generate peptides sufficiently distinct from the corresponding self-peptide to escape central tolerance and elicit a T cell response.

Frameshift and Indel-Derived Neoantigens

Insertions or deletions that are not multiples of three nucleotides shift the reading frame at the point of the mutation, causing every codon downstream of that point to be translated differently from the wild-type sequence, generating an extended stretch of entirely novel amino acid sequence rather than the single altered residue produced by a missense mutation. Because this novel downstream sequence bears no resemblance to any normal self-protein, frameshift-derived neoantigens are, on average, considerably more foreign in character than point mutation-derived neoantigens and are correspondingly associated with stronger immunogenicity per mutational event, a property particularly relevant in mismatch repair-deficient tumors, which accumulate frameshift mutations at an elevated rate due to their characteristic failure to correct insertion-deletion errors during DNA replication.

Gene Fusion-Derived Neoantigens

Chromosomal rearrangements that fuse two previously separate genes can generate a novel junctional sequence at the fusion breakpoint, producing a peptide sequence that exists only in the fusion protein and nowhere in the normal proteome, providing a further route to genuinely tumor-specific antigenic material. Because the specific breakpoint sequence depends on precisely where the two genes were joined, gene fusion neoantigens tend to be highly specific to the particular rearrangement event, distinguishing them from the broader classes of shared tumor-associated antigen that may recur across many patients' tumors independent of any specific mutation.

Splicing-Derived Antigens

Aberrant pre-mRNA splicing, whether resulting from mutations directly affecting splice site sequences or from more general dysregulation of the splicing machinery frequently observed in cancer cells, can generate novel exon-exon junctions or retained intronic sequence not present in any normal splice variant, translating into peptide sequences absent from the normal proteome despite arising from an otherwise unmutated gene. This mechanism broadens the potential source of tumor-specific antigenic material beyond direct coding sequence mutation to encompass errors introduced during RNA processing, adding a further layer to the range of antigen-generating mechanisms available even in tumors with comparatively low overall mutational burden.

Post-Translational Modification-Derived Antigens

Beyond alterations at the DNA and RNA level, cancer cells frequently display aberrant post-translational modification patterns — including altered glycosylation, in which tumor cells commonly display truncated or otherwise abnormal carbohydrate structures on cell-surface glycoproteins relative to normal tissue — that can themselves constitute or contribute to antigenic difference recognizable by the immune system, providing a mechanism for antigen generation that operates entirely independent of the underlying protein sequence and instead reflects dysregulated enzymatic processing occurring after normal translation.

Endogenous Retroelement Derepression

Cancer cells frequently exhibit widespread epigenetic derepression of endogenous retroviral elements and other transposable sequences that are normally silenced through DNA methylation in healthy tissue, and reactivated expression of these sequences can generate viral-like antigenic material and, in some contexts, trigger innate immune sensing pathways that respond to the resulting double-stranded RNA, providing yet another antigen-generating mechanism distinct from both mutation-derived and splicing-derived routes, and one linked mechanistically to the broader epigenetic dysregulation characteristic of many tumors.

Implications for Antigen Prediction and Immunotherapy Design

Because tumor antigens can arise through this range of distinct mechanisms rather than through point mutation alone, comprehensive antigen discovery for applications such as personalized cancer vaccine design increasingly integrates genomic mutation calling, RNA splicing analysis, and direct mass spectrometry-based identification of peptides actually bound to MHC molecules at the tumor cell surface (immunopeptidomics), since relying on DNA sequence mutation calling alone would systematically miss the splicing-derived, post-translationally modified, and retroelement-derived antigen categories described above, potentially underestimating a given tumor's true antigenic repertoire and limiting the completeness of any resulting antigen-targeted therapeutic strategy.